KR101183875B1 - 수용체에 결합하는 펩티드 및 화합물 - Google Patents

수용체에 결합하는 펩티드 및 화합물 Download PDF

Info

Publication number
KR101183875B1
KR101183875B1 KR1020067003755A KR20067003755A KR101183875B1 KR 101183875 B1 KR101183875 B1 KR 101183875B1 KR 1020067003755 A KR1020067003755 A KR 1020067003755A KR 20067003755 A KR20067003755 A KR 20067003755A KR 101183875 B1 KR101183875 B1 KR 101183875B1
Authority
KR
South Korea
Prior art keywords
peptide compound
peptide
nal
mepeg
alanine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020067003755A
Other languages
English (en)
Korean (ko)
Other versions
KR20070017942A (ko
Inventor
브라이언 알. 맥도날드
제프리 켄네쓰 웨이스
에드워드 존 유르코우
Original Assignee
오르토-맥네일 파마슈티칼, 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272720&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101183875(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 오르토-맥네일 파마슈티칼, 인코퍼레이티드 filed Critical 오르토-맥네일 파마슈티칼, 인코퍼레이티드
Publication of KR20070017942A publication Critical patent/KR20070017942A/ko
Application granted granted Critical
Publication of KR101183875B1 publication Critical patent/KR101183875B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
KR1020067003755A 2003-08-28 2004-08-13 수용체에 결합하는 펩티드 및 화합물 Expired - Fee Related KR101183875B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49874003P 2003-08-28 2003-08-28
US60/498,740 2003-08-28
PCT/US2004/026422 WO2005023834A2 (en) 2003-08-28 2004-08-13 Peptides and compounds that bind to thrombopoietin receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020127014067A Division KR20120078742A (ko) 2003-08-28 2004-08-13 수용체에 결합하는 펩티드 및 화합물

Publications (2)

Publication Number Publication Date
KR20070017942A KR20070017942A (ko) 2007-02-13
KR101183875B1 true KR101183875B1 (ko) 2012-09-27

Family

ID=34272720

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127014067A Withdrawn KR20120078742A (ko) 2003-08-28 2004-08-13 수용체에 결합하는 펩티드 및 화합물
KR1020067003755A Expired - Fee Related KR101183875B1 (ko) 2003-08-28 2004-08-13 수용체에 결합하는 펩티드 및 화합물

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020127014067A Withdrawn KR20120078742A (ko) 2003-08-28 2004-08-13 수용체에 결합하는 펩티드 및 화합물

Country Status (32)

Country Link
US (1) US7576056B2 (enExample)
EP (1) EP1675606B1 (enExample)
JP (1) JP4848277B2 (enExample)
KR (2) KR20120078742A (enExample)
CN (2) CN102241742B (enExample)
AR (1) AR045530A1 (enExample)
AU (1) AU2004270656B2 (enExample)
BR (1) BRPI0414008B8 (enExample)
CA (1) CA2537421C (enExample)
CY (1) CY1118965T1 (enExample)
DK (1) DK1675606T3 (enExample)
EA (1) EA009286B1 (enExample)
EC (1) ECSP066396A (enExample)
ES (1) ES2626107T3 (enExample)
HR (1) HRP20170810T1 (enExample)
HU (1) HUE032370T2 (enExample)
IL (1) IL173965A (enExample)
IS (1) IS8300A (enExample)
LT (1) LT1675606T (enExample)
ME (1) ME00313B (enExample)
MX (1) MXPA06002292A (enExample)
NO (1) NO344233B1 (enExample)
NZ (1) NZ545455A (enExample)
PL (1) PL1675606T3 (enExample)
PT (1) PT1675606T (enExample)
RS (2) RS20060141A (enExample)
SG (1) SG131110A1 (enExample)
SI (1) SI1675606T1 (enExample)
TW (1) TWI348375B (enExample)
UA (1) UA82710C2 (enExample)
WO (1) WO2005023834A2 (enExample)
ZA (1) ZA200602495B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091311B2 (en) * 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
WO2000024770A2 (en) 1998-10-23 2000-05-04 Amgen Inc. Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
BR0314591A (pt) * 2002-09-18 2005-08-09 Ortho Mcneil Pharm Inc Métodos de aumento de plaquetas e produção de célula tronco hematopoiética
US20040149235A1 (en) * 2002-10-04 2004-08-05 Pogue Albert S. Apparatus and method for removal of waste from animal production facilities
JP4848277B2 (ja) 2003-08-28 2011-12-28 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 受容体に結合するペプチドおよび化合物
US7723295B2 (en) * 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
US7615533B2 (en) 2004-08-16 2009-11-10 Janssen Pharmaceutica N.V. TPO peptide compounds for treatment of anemia
EP1986677A2 (en) * 2006-01-25 2008-11-05 Amgen Inc. Thrombopoietic compounds
EP1984014B1 (en) * 2006-02-14 2014-08-06 Janssen Pharmaceutica NV Use of tpo peptide compounds and pharmaceutical compositions in the treatment of anemia
MY151332A (en) * 2006-02-14 2014-05-15 Janssen Pharmaceutica Nv Use of tpo peptide compounds and pharmaceutical compositions in the treatment of anemia
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
KR20110015448A (ko) * 2008-06-03 2011-02-15 얀센 파마슈티카 엔.브이. 암 치료와 관련된 혈액 질환을 예방하기 위한 ｔｐｏ 모방 펩티드
WO2012176885A1 (ja) 2011-06-23 2012-12-27 株式会社 島津製作所 分岐型両親媒性ブロックポリマー、それを用いた分子集合体及び薬剤搬送システム
BR112020001367A2 (pt) * 2017-07-26 2020-08-11 Janssen Pharmaceutica N.V. métodos de proteção da integridade vascular induzida por terapia de radiação direcionada
EP3914286B1 (en) 2019-01-25 2025-05-07 Janssen Pharmaceutica NV Methods of mitigating toxic effects of vesicants and caustic gas
KR20210141460A (ko) 2019-01-25 2021-11-23 잔센파마슈티카엔.브이. 방사선 및/또는 방사선 모방체 치료와 함께 간 손상을 완화하고 간 비대, 재생 및 세포 생착을 촉진하는 방법
CA3127458A1 (en) * 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure
US20230104658A1 (en) 2021-10-01 2023-04-06 Janssen Pharmaceutica Nv Methods of increasing progenitor cell production
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5326558A (en) 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
IL96477A0 (en) 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
DK167813B1 (da) 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
US5571508A (en) 1989-12-18 1996-11-05 Amrad Corporation Limited Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor
IT1241395B (it) 1990-04-02 1994-01-10 Eniricerche Spa Composti immunogenici,il procedimento per la loro sintesi e loro impiego per la preparazione di vaccini antimalaria
US5141851A (en) 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
US5250732A (en) 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
AU680422B2 (en) 1992-06-11 1997-07-31 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
CA2150371C (en) 1992-12-11 2002-09-17 Dov Borovsky Materials and methods for control of pests
AU8124694A (en) 1993-10-29 1995-05-22 Affymax Technologies N.V. In vitro peptide and antibody display libraries
SG47030A1 (en) 1994-01-03 1998-03-20 Genentech Inc Thrombopoietin
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
WO1995021626A1 (en) 1994-02-14 1995-08-17 University Of Washington Methods for stimulating erythropoiesis using thrombopoietin
JPH09508797A (ja) 1994-02-14 1997-09-09 ザイモジェネティクス，インコーポレイティド 造血タンパク質及びそれを製造するための材料及び方法
EP0668352A1 (en) 1994-02-14 1995-08-23 Kirin Brewery Company, Ltd. Protein having TPO activity
JP2996415B2 (ja) 1994-03-31 1999-12-27 アムジエン・インコーポレーテツド 巨核球の成長と分化を刺激するモノｐｅｇ化ｍｇｄｆポリペプチド
US5571686A (en) 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
ES2145929T3 (es) * 1994-11-04 2000-07-16 Santen Pharmaceutical Co Ltd Nuevo derivado de 1,3-dialquil-urea que tiene un grupo hidroxilo.
WO1996017062A1 (en) 1994-11-30 1996-06-06 Zymogenetics, Inc. Low molecular weight thrombopoietin
US5641655A (en) 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
AU705064B2 (en) 1995-04-26 1999-05-13 Kyowa Hakko Kogyo Co. Ltd. Novel polypeptides
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6251864B1 (en) * 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
EP2055712A1 (en) 1995-06-07 2009-05-06 Glaxo Group Limited Peptides and compounds that bind to a thrombopoietin receptor
US6060052A (en) 1995-10-30 2000-05-09 Systemix, Inc. Methods for use of Mpl ligands with primitive human hematopoietic stem cells
US5932546A (en) 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
WO2001021180A1 (en) 1999-09-24 2001-03-29 Smithkline Beecham Corporation Thrombopoietin mimetics
ES2266104T3 (es) * 2000-12-22 2007-03-01 Ipsen Manufacturing Ireland Limited Procedimiento para la sintesis de un peptido lhrh.
WO2002078612A2 (en) 2001-04-02 2002-10-10 Euro-Celtique S.A. Thrombopoietin (tpo) synthebody for stimulation of platelet production
BR0314591A (pt) * 2002-09-18 2005-08-09 Ortho Mcneil Pharm Inc Métodos de aumento de plaquetas e produção de célula tronco hematopoiética
JP4848277B2 (ja) 2003-08-28 2011-12-28 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 受容体に結合するペプチドおよび化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Stem Cells. 1999;17(6):316-26..*

Also Published As

Publication number Publication date
ME00313B (me) 2011-05-10
AU2004270656A1 (en) 2005-03-17
JP2007504132A (ja) 2007-03-01
ZA200602495B (en) 2007-06-27
EP1675606B1 (en) 2017-04-05
CA2537421A1 (en) 2005-03-17
AU2004270656B2 (en) 2011-03-10
PL1675606T3 (pl) 2017-08-31
NZ545455A (en) 2009-02-28
MEP48508A (en) 2011-02-10
PT1675606T (pt) 2017-05-22
BRPI0414008A (pt) 2006-10-24
HRP20170810T1 (hr) 2017-08-11
IL173965A (en) 2015-10-29
SI1675606T1 (sl) 2017-07-31
EA200600477A1 (ru) 2007-02-27
CY1118965T1 (el) 2018-01-10
TWI348375B (en) 2011-09-11
KR20120078742A (ko) 2012-07-10
SG131110A1 (en) 2007-04-26
CN102241742B (zh) 2014-04-02
BRPI0414008B1 (pt) 2018-05-15
DK1675606T3 (en) 2017-06-19
EP1675606A4 (en) 2009-09-30
UA82710C2 (uk) 2008-05-12
US20050137133A1 (en) 2005-06-23
IS8300A (is) 2006-02-14
AR045530A1 (es) 2005-11-02
BRPI0414008B8 (pt) 2021-05-25
WO2005023834A2 (en) 2005-03-17
MXPA06002292A (es) 2006-09-04
IL173965A0 (en) 2006-07-05
HK1096873A1 (en) 2007-06-15
LT1675606T (lt) 2017-11-10
CN102241742A (zh) 2011-11-16
RS56387B1 (sr) 2017-12-29
CN1871022B (zh) 2011-07-06
EP1675606A2 (en) 2006-07-05
KR20070017942A (ko) 2007-02-13
NO20061346L (no) 2006-05-22
JP4848277B2 (ja) 2011-12-28
EA009286B1 (ru) 2007-12-28
ES2626107T3 (es) 2017-07-24
ECSP066396A (es) 2006-08-30
TW200517103A (en) 2005-06-01
NO344233B1 (no) 2019-10-14
US7576056B2 (en) 2009-08-18
CA2537421C (en) 2011-09-27
CN1871022A (zh) 2006-11-29
WO2005023834A3 (en) 2005-05-06
HUE032370T2 (en) 2017-09-28
RS20060141A (sr) 2008-08-07

Similar Documents

Publication Publication Date Title
US6251864B1 (en) Peptides and compounds that bind to a receptor
KR101183875B1 (ko) 수용체에 결합하는 펩티드 및 화합물
NO344405B1 (no) Peptidforbindelse som binder til TPO reseptor for terapeutisk behandling av blodplateforstyrrelse eller trombocytopeni hos mennesker
HK1123811B (en) Use of peptides that bind to tpo receptor
HK1163698B (en) Peptides and compounds that bind to a receptor
HK1163698A (en) Peptides and compounds that bind to a receptor
HK1096873B (en) Peptides and compounds that bind to thrombopoietin receptors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

N231 Notification of change of applicant
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

A107 Divisional application of patent
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A17-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20150913

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20150913

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000